Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in hundreds of millions of dollars through its upcoming public debut. The ...

There are no signs so far that the new LB.1 variant is causing more severe disease in COVID-19 patients, the Centers for Disease Control and Prevention says, as infections have begun to accelerate in ...

As COVID-19 cases continue to rise across the United States, scientists are monitoring the spread of a new variant called LB.1. The highly contagious omicron subvariant, along with the fast-growing ...

After a promising start, biotech IPOs all but fizzled out this year, but LB Pharmaceuticals is hoping that won't stymy its chances of completing a Nasdaq listing. New York-based LB is hoping to raise ...

Byers played for the team from 1983 to 1992 and went to the Stanley Cup finals twice before becoming a Boston radio personality Paul Marotta/Getty Lyndon “LB” Byers, the former Boston Bruins player ...

The Centers for Disease Control and Prevention (CDC) is tracking the growth of the COVID-19 LB.1 variant as it begins to trail KP.3. For a two-week period starting on June 9 and ending on June 22, the ...

(LBRX) on Tuesday reported a loss of $19.1 million in its first quarter. The New York-based company said it had a loss of 67 cents per share.